{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:35:32Z","timestamp":1768962932120,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100013928","name":"Millennium Institute on Immunology and Immunotherapy","doi-asserted-by":"crossref","award":["ICN09_016 \/ ICN 2021_045; former P09\/016-F"],"award-info":[{"award-number":["ICN09_016 \/ ICN 2021_045; former P09\/016-F"]}],"id":[{"id":"10.13039\/501100013928","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N9301900065"],"award-info":[{"award-number":["75N9301900065"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016014","name":"Fondo de Innovaci\u00f3n para la Competitividad","doi-asserted-by":"publisher","award":["BIP Code: 30488811-0"],"award-info":[{"award-number":["BIP Code: 30488811-0"]}],"id":[{"id":"10.13039\/501100016014","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04535-8","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:08:55Z","timestamp":1765804135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A booster dose of an inactivated SARS-CoV-2 vaccine targeting virus variants sustains protective humoral and cellular immunity"],"prefix":"10.1186","volume":"24","author":[{"given":"Constanza","family":"M\u00e9ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linmar","family":"Rodr\u00edguez-Guilarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo A.","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Gutierrez-Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Moreno-Tapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"R\u00edos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe A.","family":"Cancino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco F.","family":"Otero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constanza","family":"Zurita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa F.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela","family":"Urz\u00faa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Iturriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos M.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Schilling","family":"Redlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo A.","family":"Fasce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang\u00e9lica","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Weiskopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Grifoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Sette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weining","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Goldbatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"CoronaVarCL study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 V.","family":"Gonz\u00e1lez-Aramundiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J.","family":"\u00c1lvarez-Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Abarca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandro J.","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo A.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis M.","family":"Kalergis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hern\u00e1n F.","family":"Pe\u00f1aloza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"4535_CR1","unstructured":"COVID-19 - global situation. Available from: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2025-DON572.\u00a0Accessed 9 Jun 2025."},{"key":"4535_CR2","unstructured":"Coronavirus (COVID-19) Vaccinations - our world in data. Available from: https:\/\/ourworldindata.org\/covid-vaccinations?country=OWID_WRL.\u00a0Accessed 9 Jun 2025."},{"issue":"3","key":"4535_CR3","first-page":"162","volume":"21","author":"AM Carabelli","year":"2023","unstructured":"Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, de Silva TI, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21(3):162\u201377.","journal-title":"Nat Rev Microbiol"},{"key":"4535_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.10.102","volume":"538","author":"M Giovanetti","year":"2021","unstructured":"Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G, et al. Evolution patterns of SARS-CoV-2: snapshot on its genome variants. Biochem Biophys Res Commun. 2021;538:88.","journal-title":"Biochem Biophys Res Commun"},{"key":"4535_CR5","doi-asserted-by":"crossref","unstructured":"Cocherie T, Zafilaza K, Leducq V, Marot S, Calvez V, Marcelin AG, et al. Epidemiology and characteristics of SARS-CoV-2 variants of concern: The impacts of the spike mutations. Microorganisms. 2022;11(1):30.","DOI":"10.3390\/microorganisms11010030"},{"issue":"1","key":"4535_CR6","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i1.1","volume":"10","author":"SY Ren","year":"2022","unstructured":"Ren SY, Gao RD, Wang WB, zhou AM. Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance. World J Clin Cases. 2022;10(1):1.","journal-title":"World J Clin Cases"},{"key":"4535_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104563","volume":"91","author":"C M\u00e9ndez","year":"2023","unstructured":"M\u00e9ndez C, Pe\u00f1aloza HF, Schultz BM, Pi\u00f1a-Iturbe A, R\u00edos M, Moreno-Tapia D, et al. Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults. EBioMedicine. 2023;91:104563.","journal-title":"EBioMedicine"},{"issue":"16","key":"4535_CR8","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532\u201346.","journal-title":"N Engl J Med"},{"key":"4535_CR9","unstructured":"ECDC de-escalates BA.2, BA.4 and BA.5 from its list of variants of concern. Available from: https:\/\/www.ecdc.europa.eu\/en\/news-events\/ecdc-de-escalates-ba2-ba4-and-ba5-its-list-variants-concern.\u00a0Accessed 25 Jun 2025."},{"key":"4535_CR10","unstructured":"COVID-19 variants | WHO COVID-19 dashboard . Available from: https:\/\/data.who.int\/dashboards\/covid19\/variants.\u00a0Accessed 9 Jun 2025."},{"key":"4535_CR11","unstructured":"COVID-19 epidemiological update \u2013 17 May 2024. Available from: https:\/\/www.who.int\/publications\/m\/item\/covid-19-epidemiological-update-edition-167.\u00a0Accessed 25 Jun 2025."},{"key":"4535_CR12","doi-asserted-by":"crossref","unstructured":"Mojadadi MS, Javadinia SA, Attarian F, Samami E, Sobhani M. Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: a systematic review with meta-analysis of heterologous versus homologous vaccination. Front Public Health. 2022;10.","DOI":"10.3389\/fpubh.2022.960598"},{"key":"4535_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51427-1","author":"CA Cohen","year":"2024","unstructured":"Cohen CA, Leung NHL, Kaewpreedee P, Lee KWK, Jia JZ, Cheung AWL, et al. Antibody Fc receptor binding and T cell responses to homologous and heterologous immunization with inactivated or mRNA vaccines against SARS-CoV-2. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-51427-1.","journal-title":"Nat Commun"},{"key":"4535_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01423-22","author":"BM Schultz","year":"2022","unstructured":"Schultz BM, Melo-Gonz\u00e1lez F, Duarte LF, G\u00e1lvez NMS, Pacheco GA, Soto JA, et al. A booster dose of CoronaVac increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern. MBio. 2022. https:\/\/doi.org\/10.1128\/mbio.01423-22.","journal-title":"MBio"},{"issue":"2","key":"4535_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1056\/NEJMc2214293","volume":"388","author":"ME Davis-Gardner","year":"2023","unstructured":"Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster. N Engl J Med. 2023;388(2):183\u20135.","journal-title":"N Engl J Med"},{"key":"4535_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4813199","author":"F Dapporto","year":"2022","unstructured":"Dapporto F, Marchi S, Leonardi M, Piu P, Lovreglio P, Decaro N, et al. Antibody avidity and neutralizing response against SARS-CoV-2 Omicron variant after infection or vaccination. J Immunol Res. 2022. https:\/\/doi.org\/10.1155\/2022\/4813199.","journal-title":"J Immunol Res"},{"key":"4535_CR17","doi-asserted-by":"publisher","first-page":"1372193","DOI":"10.3389\/fimmu.2024.1372193","volume":"15","author":"D Rivera-P\u00e9rez","year":"2024","unstructured":"Rivera-P\u00e9rez D, M\u00e9ndez C, Diethelm-Varela B, Melo-Gonz\u00e1lez F, V\u00e1zquez Y, Meng X, et al. Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents. Front Immunol. 2024;15:1372193.","journal-title":"Front Immunol"},{"issue":"2","key":"4535_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/cid\/ciae559","volume":"80","author":"JP Townsend","year":"2025","unstructured":"Townsend JP, Hassler HB, Dornburg A. Optimal annual COVID-19 vaccine boosting dates following previous booster vaccination or breakthrough infection. Clin Infect Dis. 2025;80(2):316\u201322.","journal-title":"Clin Infect Dis"},{"key":"4535_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01311-22","author":"JA Soto","year":"2022","unstructured":"Soto JA, Melo-Gonz\u00e1lez F, Gutierrez-Vera C, Schultz BM, Berr\u00edos-Rojas RV, Rivera-P\u00e9rez D, et al. Inactivated vaccine-induced SARS-CoV-2 variant-specific immunity in children. MBio. 2022. https:\/\/doi.org\/10.1128\/mbio.01311-22.","journal-title":"MBio"},{"issue":"11","key":"4535_CR20","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/s41591-022-02031-7","volume":"28","author":"S Chalkias","year":"2022","unstructured":"Chalkias S, Eder F, Essink B, Khetan S, Nestorova B, Feng J, et al. Safety, immunogenicity and antibody persistence of a bivalent beta-containing booster vaccine against COVID-19: a phase 2\/3 trial. Nat Med. 2022;28(11):2388.","journal-title":"Nat Med"},{"issue":"48","key":"4535_CR21","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.15585\/mmwr.mm7148e1","volume":"71","author":"R Link-Gelles","year":"2022","unstructured":"Link-Gelles R, Ciesla AA, Fleming-Dutra KE, Smith ZR, Britton A, Wiegand RE, et al. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection \u2014 increasing community access to testing program, United States, September\u2013November 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1526\u201330.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"4535_CR22","doi-asserted-by":"crossref","unstructured":"Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden L (R), et al. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat Med. 2023;29:2334\u20132346.","DOI":"10.1038\/s41591-023-02503-4"},{"issue":"8","key":"4535_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ageing\/afad141","volume":"52","author":"O Stirrup","year":"2023","unstructured":"Stirrup O, Shrotri M, Adams NL, Krutikov M, Azmi B, Monakhov I, et al. Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI study. Age Ageing. 2023;52(8):1\u20135.","journal-title":"Age Ageing"},{"key":"4535_CR24","doi-asserted-by":"crossref","unstructured":"Tauzin A, Beaun-Bussi\u00e8res G, Benlarbi M, Nayrac M, Bo Y, Gendron-Lepage G, et al. Humoral responses elicited after a fifth dose of SARS-CoV-2 mRNA bivalent vaccine. Viruses. 2023;15(9):1926.","DOI":"10.3390\/v15091926"},{"issue":"2","key":"4535_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","volume":"29","author":"C Kurhade","year":"2022","unstructured":"Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2022;29(2):344\u20137.","journal-title":"Nat Med"},{"issue":"7","key":"4535_CR26","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.immuni.2024.06.009","volume":"57","author":"JG Cyster","year":"2024","unstructured":"Cyster JG, Wilson PC. Antibody modulation of B cell responses\u2014incorporating positive and negative feedback. Immunity. 2024;57(7):1466\u201381.","journal-title":"Immunity"},{"key":"4535_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijid.2023.06.010","volume":"134","author":"A Vergori","year":"2023","unstructured":"Vergori A, Matusali G, Lepri AC, Cimini E, Fusto M, Colavita F, et al. Neutralizing activity and T cell response after bivalent fifth dose of mRNA vaccine in person living with HIV. Int J of Infect Dis. 2023;134:195\u20139.","journal-title":"Int J of Infect Dis"},{"key":"4535_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1240425","volume":"14","author":"Y Tani","year":"2023","unstructured":"Tani Y, Takita M, Wakui M, Saito H, Nishiuchi T, Zhao T, et al. Five doses of the mRNA vaccination potentially suppress ancestral-strain stimulated SARS-CoV2-specific cellular immunity: a cohort study from the Fukushima vaccination community survey, Japan. Front Immunol. 2023;14:1240425.","journal-title":"Front Immunol"},{"issue":"6","key":"4535_CR29","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/j.jhep.2023.12.008","volume":"80","author":"JJH Smeets","year":"2024","unstructured":"Smeets JJH, van Malenstein H, van der Merwe S, Nevens F, Verbeek J. SARS-CoV-2 anti-spike IgG antibodies are present in all liver transplant recipients after fifth vaccine dose. J Hepatol. 2024;80(6):e284\u20136.","journal-title":"J Hepatol"},{"issue":"4","key":"4535_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/1744-9987.14114","volume":"28","author":"K Fujieda","year":"2024","unstructured":"Fujieda K, Tanaka A, Kikuchi R, Takai N, Saito S, Yasuda Y, et al. Changes in antibody titer after four and five doses of the SARS-CoV-2 vaccine in Japanese post-kidney transplant patients. Ther Apher Dial. 2024;28(4):489\u201398.","journal-title":"Ther Apher Dial"},{"issue":"8","key":"4535_CR31","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.healun.2023.03.016","volume":"42","author":"Y Peled","year":"2023","unstructured":"Peled Y, Afek A, Patel JK, Raanani E, Segev A, Ram E, et al. Fifth bivalent omicron BA.4\/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients. J Heart Lung Transplant. 2023;42(8):1054\u20138.","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"4535_CR32","doi-asserted-by":"publisher","first-page":"e792","DOI":"10.1093\/cid\/ciab823","volume":"75","author":"SM Bueno","year":"2022","unstructured":"Bueno SM, Abarca K, Gonz\u00e1lez PA, G\u00e1lvez NMS, Soto JA, Duarte LF, et al. Safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in a subgroup of healthy adults in Chile. Clin Infect Dis. 2022;75(1):e792.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"4535_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.747830","volume":"9","author":"F Melo-Gonz\u00e1lez","year":"2021","unstructured":"Melo-Gonz\u00e1lez F, Soto JA, Gonz\u00e1lez LA, Fern\u00e1ndez J, Duarte LF, Schultz BM, et al. Recognition of variants of concern by antibodies and T cells induced by a SARS-CoV-2 inactivated vaccine. Front Immunol. 2021;9(12):747830.","journal-title":"Front Immunol"},{"issue":"7","key":"4535_CR34","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489-1501.e15.","journal-title":"Cell"},{"key":"4535_CR35","doi-asserted-by":"crossref","unstructured":"Rom\u00e1n F, Reyes A, Guti\u00e9rrez C, Rodr\u00edguez-Guilarte L, M\u00e9ndez C, et al. T cell response evaluation after a fifth dose of an inactivated SARS-CoV-2 vaccine using multiparametric flow cytometry. Eur J Immunol. 2025;55(7):e51848.","DOI":"10.1002\/eji.202551848"},{"key":"4535_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1220600","volume":"14","author":"APM Franco-Luiz","year":"2023","unstructured":"Franco-Luiz APM, Fernandes NMGS, Silva TBdeS, Bernardes WPdeOS, Westin MR, Santos TG, et al. Longitudinal study of humoral immunity against SARS-CoV-2 of health professionals in Brazil: the impact of booster dose and reinfection on antibody dynamics. Front Immunol. 2023;14:1220600.","journal-title":"Front Immunol"},{"issue":"17","key":"4535_CR37","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1056\/NEJMoa2201688","volume":"386","author":"O Magen","year":"2022","unstructured":"Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hern\u00e1n MA, et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2022;386(17):1603\u201314.","journal-title":"N Engl J Med"},{"issue":"1","key":"4535_CR38","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2665-9913(23)00272-2","volume":"6","author":"JS Hanberg","year":"2024","unstructured":"Hanberg JS, Fu X, Wang X, Patel NJ, Kawano Y, Schiff A, et al. Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial. Lancet Rheumatol. 2024;6(1):e21-30.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"4535_CR39","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1038\/s41467-024-45549-9","volume":"15","author":"HJ Park","year":"2024","unstructured":"Park HJ, Gonsalves GS, Tan ST, Kelly JD, Rutherford GW, Wachter RM, et al. Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. Nat Commun. 2024;15(1):1883.","journal-title":"Nat Commun"},{"issue":"6","key":"4535_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12060564","volume":"12","author":"S Walmsley","year":"2024","unstructured":"Walmsley S, Nabipoor M, Qi F, Lovblom LE, Ravindran R, Colwill K, et al. Declining levels of neutralizing antibodies to SARS-CoV-2 Omicron variants are enhanced by hybrid immunity and original\/Omicron bivalent vaccination. Vaccines. 2024;12(6):564.","journal-title":"Vaccines"},{"issue":"47","key":"4535_CR41","doi-asserted-by":"publisher","first-page":"E1599","DOI":"10.1503\/cmaj.221335","volume":"194","author":"DM Skowronski","year":"2022","unstructured":"Skowronski DM, Kaweski SE, Irvine MA, Kim S, Chuang ESY, Sabaiduc S, et al. Serial cross-sectional estimation of vaccine and infection-induced SARS-CoV-2 seroprevalence in British Columbia. Canada CMAJ. 2022;194(47):E1599\u2013609.","journal-title":"Canada CMAJ"},{"key":"4535_CR42","doi-asserted-by":"crossref","unstructured":"Voss WN, Mallory MA, Byrne PO, Marchioni JM, Knudson SA, Powers JM, et al. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination. Cell Rep Med. 2024;101668.","DOI":"10.1101\/2024.01.22.576742"},{"issue":"11\u201312","key":"4535_CR43","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0264-410X(01)00490-X","volume":"20","author":"BE Johansson","year":"2002","unstructured":"Johansson BE, Pokorny BA, Tiso VA. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine. 2002;20(11\u201312):1670\u20134.","journal-title":"Vaccine"},{"issue":"4","key":"4535_CR44","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ymthe.2024.02.011","volume":"32","author":"N Wu","year":"2024","unstructured":"Wu N, Zhang J, Shen Y, Zhang X, Zhou J, Wu Y, et al. A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections. Mol Ther. 2024;32(4):1033\u201347.","journal-title":"Mol Ther"},{"issue":"5","key":"4535_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.07.024","volume":"85","author":"JY Noh","year":"2022","unstructured":"Noh JY, Cheong HJ, Kim WJ, Choi JY, Lee HW, Kim SS, et al. Robust neutralizing antibody responses after single-dose BNT162b2 vaccination at long intervals from prior SARS-CoV-2 infection and ceiling effect with repeated vaccination. J Infect. 2022;85(5):573.","journal-title":"J Infect"},{"key":"4535_CR46","doi-asserted-by":"crossref","unstructured":"Sun K, Tempia S, Kleynhans J, von Gottberg A, McMorrow ML, Wolter N, et al. Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa. Nat Commun. 2023;14(1):1\u201313.","DOI":"10.1038\/s41467-022-35652-0"},{"key":"4535_CR47","doi-asserted-by":"crossref","unstructured":"Hachmann NP, Miller J, Collier A ris Y, Ventura JD, Yu J, Rowe M, et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. New England J Med. 2022;387(1):86\u20138.","DOI":"10.1056\/NEJMc2206576"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04535-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04535-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04535-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:25:11Z","timestamp":1768919111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-025-04535-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4535"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04535-8","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Scientific and Ethical Committee of Health Sciences at Pontificia Universidad Cat\u00f3lica de Chile reviewed and approved the current study protocol (no. 220509011). The trial was approved by the Chilean Public Health Institute (ISP Chile) (no. 22623\u201322) and conducted according to the current ICH-GCP E6(R2) guidelines, the Declaration of Helsinki, and local regulations. Informed consent was obtained from all volunteers upon enrollment. Written informed consent was obtained from all participants prior to their enrollment in the study. Members of the CoronaVarCL study group are listed in the Additional file 1.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GZ and WM are SINOVAC Biotech employees and contributed to the conceptualization of the study (clinical protocol and eCRF design) and did not participate in the analysis or interpretation of the data presented in the manuscript. A.S. is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Moderna, AstraZeneca, Avalia, Fortress, Repertoire, Gilead, Gerson Lehrman Group, RiverVest, MedaCorp, and Guggenheim. La Jolla Institute for Immunology (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}